New model requires proof of quality

Share this article:
ACCME revamped its accreditation model, giving providers until 2008 to comply. While the model exhorts them to start plotting changes to the way they plan and deliver activities, a lack of specificity makes that challenging.

The model ties accreditation to medical practice by requiring providers demonstrate that their activities improve quality, from an efficacy and safety standpoint—a similar model is being adopted by those who fund education.

“As always, the manner of implementation is the decision of the leadership of each provider,” said Murray Kopelow, MD, ACCME chief executive. By assessing how they facilitate change in competence, performance or patient outcomes, providers can begin implementation, he added.

The general consensus from MECCs, specialty societies, medical schools and large associations is that the model moves CME in the right direction. “Most of us have been working really hard to get toward performance improvement and really documenting that from our CME,” said Nancy Davis, PhD, director, division of CME, American Academy of Family Physicians. “This is going to be the stimulus to get all providers thinking along those lines.”

But, she added, ambiguity is a hurdle. “That's one of the challenges to know what ACCME has in mind with the guidelines: Just knowing what the expectation is.”

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Judge blocks FDA bid to allow generic Precedex

Judge blocks FDA bid to allow generic Precedex

The US District Court for Maryland granted Hospira a temporary restraining order (TRO) against FDA, after the agency determined that potential generic competitors of the company's injectable sedation drug Precedex ...

GSK drug gets aplastic anemia indication

GSK drug gets aplastic anemia indication

Promacta was previously indicated for chronic immune thrombocytopenia.

Five things for Pharma Marketers to know: Wednesday, August 27

Five things for Pharma Marketers to know: Wednesday, ...

Allergan sets a shareholder voting date, Novo describes the types of acquisitions it will consider, and the AstraZeneca-Pfizer talks can now reopen.